Aquablation Therapy for Prostate Cancer

This trial investigates Aquablation therapy, a new treatment option, to assess its safety and effectiveness for men with localized prostate cancer. Aquablation uses water jets controlled by robotic systems to remove prostate tissue. The trial compares two groups: one receiving Aquablation therapy and the other under standard observation, known as active surveillance. Men diagnosed with prostate cancer within the last 18 months who have not yet received treatment may be suitable candidates for this study.

As an unphased trial, this study provides patients the opportunity to explore a cutting-edge treatment option that could potentially enhance their quality of life.

Previous studies have shown that Aquablation therapy is quite safe for treating prostate issues. One study found that Aquablation led to fewer problems with ejaculation (release of sperm) compared to another common procedure, with only 10% of patients experiencing this side effect, compared to 36% in the other group. Another study showed that even after five years, the need for further treatment remained very low, at just 3.7%. This suggests that the therapy is both safe and effective over the long term. Additionally, reports indicate that Aquablation improves urinary function while maintaining stable sexual function. Overall, research indicates that the treatment is well-tolerated with few adverse effects.¹²³⁴⁵

Aquablation Therapy for prostate cancer is unique because it uses a robotic system to deliver a high-velocity water jet to precisely remove prostate tissue. Unlike traditional treatments like surgery or radiation, which can have significant side effects, this method offers a minimally invasive approach with potentially fewer complications. Researchers are excited about this treatment because it promises greater precision and reduced recovery time, which could improve patients' quality of life while maintaining effective cancer control.

Studies have shown that Aquablation therapy can effectively shrink the prostate and improve urinary symptoms. For example, one study found that prostate size reduced by an average of 41.3% after one year. Most men who underwent Aquablation therapy continued normal activities like urinating and ejaculating. Additionally, three men with prostate cancer underwent the procedure and experienced positive results. In this trial, participants in the Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or the HYDROS Robotic System. Early signs suggest that Aquablation therapy might be a promising option for treating localized prostate cancer.⁶⁷⁸⁹¹⁰